Financhill
Sell
11

CATX Quote, Financials, Valuation and Earnings

Last price:
$3.05
Seasonality move :
15.07%
Day range:
$3.13 - $3.29
52-week range:
$2.70 - $19.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.96x
P/B ratio:
0.65x
Volume:
416K
Avg. volume:
973K
1-year change:
-65.12%
Market cap:
$212.2M
Revenue:
--
EPS (TTM):
-$1.46

Analysts' Opinion

  • Consensus Rating
    Perspective Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 1 Hold rating, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $15.61, Perspective Therapeutics has an estimated upside of 411.15% from its current price of $3.14.
  • Price Target Downside
    According to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $3.14.

Fair Value

  • According to the consensus of 8 analysts, Perspective Therapeutics has 411.15% upside to fair value with a price target of $15.61 per share.

CATX vs. S&P 500

  • Over the past 5 trading days, Perspective Therapeutics has underperformed the S&P 500 by -6.04% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Perspective Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Perspective Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Perspective Therapeutics reported revenues of --.

Earnings Growth

  • Perspective Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Perspective Therapeutics reported earnings per share of -$0.21.
Enterprise value:
-53.9M
EV / Invested capital:
--
Price / LTM sales:
16.96x
EV / EBIT:
--
EV / Revenue:
-5.42x
PEG ratio (5yr expected):
-0.26x
EV / Free cash flow:
1.33x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $9.9M $7M -- $1.9M --
Gross Profit $4M -- -- -- --
Operating Income -$9.3M -$33.5M -$57.6M -$9.8M -$18.6M
EBITDA -$9.1M -$31.9M -$47.8M -$9.3M -$14.4M
Diluted EPS -$0.60 -$1.07 -$1.46 -$0.37 -$0.21
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $4.7M $65M $57.5M $21.7M $270.2M
Total Assets $8M $68.7M $62.5M $110.5M $391.2M
Current Liabilities $1.5M $1.8M $4M $8.1M $28.1M
Total Liabilities $2.9M $3M $4.8M $11.7M $62.7M
Total Equity $5.1M $65.8M $57.7M $98.8M $328.5M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$7.4M -$29.7M -$696K -$10.1M $3.4M
Cash From Investing -$35.4M -$10.7M -$80.4M -$227K -$29.7M
Cash From Financing $84K $461K $289.4M $1K $628K
Free Cash Flow -$7.7M -$30.7M -$40.6M -$10.3M -$26.3M
CATX
Sector
Market Cap
$212.2M
$43.5M
Price % of 52-Week High
16.48%
47.5%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-65.12%
-35.82%
Beta (5-Year)
1.220
0.753
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $3.36
200-day SMA
Sell
Level $10.55
Bollinger Bands (100)
Sell
Level 3 - 11.64
Chaikin Money Flow
Sell
Level -323.7M
20-day SMA
Sell
Level $3.48
Relative Strength Index (RSI14)
Sell
Level 38.94
ADX Line
Sell
Level 18.83
Williams %R
Buy
Level -99.0991
50-day SMA
Sell
Level $3.48
MACD (12, 26)
Sell
Level -0.15
25-day Aroon Oscillator
Buy
Level 20
On Balance Volume
Neutral
Level 532.1M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Stock Forecast FAQ

In the current month, CATX has received 7 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CATX average analyst price target in the past 3 months is $15.61.

  • Where Will Perspective Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Perspective Therapeutics share price will rise to $15.61 per share over the next 12 months.

  • What Do Analysts Say About Perspective Therapeutics?

    Analysts are divided on their view about Perspective Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Perspective Therapeutics is a Sell and believe this share price will drop from its current level to $6.00.

  • What Is Perspective Therapeutics's Price Target?

    The price target for Perspective Therapeutics over the next 1-year time period is forecast to be $15.61 according to 8 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.

  • Is CATX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Perspective Therapeutics is a Buy. 7 of 8 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of CATX?

    You can purchase shares of Perspective Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Perspective Therapeutics shares.

  • What Is The Perspective Therapeutics Share Price Today?

    Perspective Therapeutics was last trading at $3.05 per share. This represents the most recent stock quote for Perspective Therapeutics. Yesterday, Perspective Therapeutics closed at $3.14 per share.

  • How To Buy Perspective Therapeutics Stock Online?

    In order to purchase Perspective Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock